Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
Avio Smart Market Stack Limited and Huwel Lifesciences unveil portable, cost-efficient molecular testing platform
Former Novo Nordisk and Pharmanovia executive to lead next growth phase in NAD diagnostics and personalised health innovation
With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
In his new role, Gregory will drive partnerships for the company’s large-scale molecule biologics business across Europe
Experts call for integrated, evidence-based approaches to tackle rising dengue, malaria, and chikungunya burden in Indian cities
His appointment is expected to strengthen scientific input in policy discussions across public health, biotech, and translational research
Over the past decade, IIL has maintained a strong growth trajectory, registering a compound annual growth rate (CAGR) of 16%
_256_384.jpg)
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
Subscribe To Our Newsletter & Stay Updated
